Literature DB >> 11697537

Human lactoferrin: a novel therapeutic with broad spectrum potential.

E D Weinberg1.   

Abstract

Lactoferrin (Lf), a natural defence iron-binding protein, has been found to possess antibacterial, antimycotic, antiviral, antineoplastic and anti-inflammatory activity. The protein is present in exocrine secretions that are commonly exposed to normal flora: milk, tears, nasal exudate, saliva, bronchial mucus, gastrointestinal fluids, cervico-vaginal mucus and seminal fluid. Additionally, Lf is a major constituent of the secondary specific granules of circulating polymorphonuclear neutrophils (PMNs). The apoprotein is released on degranulation of the PMNs in septic areas. A principal function of Lf is that of scavenging free iron in fluids and inflamed areas so as to suppress free radical-mediated damage and decrease the availability of the metal to invading microbial and neoplastic cells. Mechanisms of action of Lf in addition to iron deprivation are also described. Administration of exogenous human or bovine Lf to hosts with various infected or inflamed sites has resulted in some prophylactic or therapeutic effects. However, an adverse response to the protein might occur if it were to stimulate antibody production or if it were to provide iron to the invading pathogen. The recombinant form of human Lf has become available and development of the product for use in a wide range of medical conditions can now be anticipated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697537     DOI: 10.1211/0022357011777792

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  32 in total

1.  Salivary analyses and caries increment over 4 years: an approach by cluster analysis.

Authors:  H Jentsch; E Beetke; R Göcke
Journal:  Clin Oral Investig       Date:  2004-04-15       Impact factor: 3.573

2.  Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin.

Authors:  Shaper Mirza; Landon Wilson; William H Benjamin; Jan Novak; Stephen Barnes; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

Review 3.  Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?

Authors:  P R Gibson; J G Muir
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

4.  The influence of iron availability on human salivary microbial community composition.

Authors:  Renke Wang; Aida Kaplan; Lihong Guo; Wenyuan Shi; Xuedong Zhou; Renate Lux; Xuesong He
Journal:  Microb Ecol       Date:  2012-02-09       Impact factor: 4.552

5.  Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN.

Authors:  William C Adams; Emily Bond; Menzo J E Havenga; Lennart Holterman; Jaap Goudsmit; Gunilla B Karlsson Hedestam; Richard A Koup; Karin Loré
Journal:  J Gen Virol       Date:  2009-03-12       Impact factor: 3.891

6.  Iron status in mice carrying a targeted disruption of lactoferrin.

Authors:  Pauline P Ward; Marisela Mendoza-Meneses; Grainne A Cunningham; Orla M Conneely
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

7.  Amoebicidal activity of milk, apo-lactoferrin, sIgA and lysozyme.

Authors:  Nidia León-Sicairos; Fernando López-Soto; Magda Reyes-López; Delfino Godínez-Vargas; Cynthia Ordaz-Pichardo; Mireya de la Garza
Journal:  Clin Med Res       Date:  2006-06

8.  Comparison of the antimicrobial adhesion potential of human body fluid glycoconjugates using fucose-binding lectin (PA-IIL) of Pseudomonas aeruginosa and Ulex europaeus lectin (UEA-I).

Authors:  Batia Lerrer; Efrat Lesman-Movshovich; Nechama Gilboa-Garber
Journal:  Curr Microbiol       Date:  2005-08-02       Impact factor: 2.188

Review 9.  Lactoferrin--a novel bone growth factor.

Authors:  Dorit Naot; Andrew Grey; Ian R Reid; Jillian Cornish
Journal:  Clin Med Res       Date:  2005-05

10.  Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells.

Authors:  Cecilia Johansson; Mari Jonsson; Marko Marttila; David Persson; Xiao-Long Fan; Johan Skog; Lars Frängsmyr; Göran Wadell; Niklas Arnberg
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.